{"status": "Ok", "redirect_url": "https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizers-ELREXFIO-Significantly-Improves-Progression-Free-Survival-for-Double-Class-Exposed-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx", "message": "News view counter 688161 successfully enlarged"}